CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a serbian cohort of HIV patients

Therapeutic Drug Monitoring

Volumn 36, Issue 6, 2014, Pages 734-738

  Olagunju, Adeniyi ^a,b   Siccardi, Marco ^a   Amara, Alieu ^a   Jevtovic, Djordje ^c   Kusic, Jovana ^c   Owen, Andrew ^a   Dragovic, Gordana ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

constitutive androstane receptor; CYP2B6 516G>T; efavirenz; pharmacogenetics; rs3745274

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; BENZOXAZINE DERIVATIVE; CYTOCHROME P450 2B6 INDUCER;

ADULT; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CYP2B6 GENE; DRUG BLOOD LEVEL; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERBIA; SERBIAN (CITIZEN); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TANDEM MASS SPECTROMETRY; BLOOD; GENETICS; HIV INFECTIONS; MIDDLE AGED;

ADULT; BENZOXAZINES; COHORT STUDIES; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2B6 INDUCERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SERBIA; SMOKING;

EID: 84930085580     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000098     Document Type: Article

References (29)

1. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15: 71-75
2. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008; 13: 675-685
3. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003; 306: 287-300
4. Faucette SR, Zhang T-C, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007; 320: 72-80
5. Faucette SR, Sueyoshi T, Smith CM, et al. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther. 2006; 317: 1200-1209
6. Cortes CP, Siccardi M, Chaikan A, et al. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit. 2013; 35: 78-83
7. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T . C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61: 914-918
8. Swart M, Skelton M, Ren Y, et al. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics. 2013; 23: 415-427
9. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012; 22: 858-867
10. Swart M, Whitehorn H, Ren Y, et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet. 2012; 13: 112
11. Washio I, Maeda M, Sugiura C, et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos. 2011; 39: 1-3
12. Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmcol. 2004; 199: 251-265
13. Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother. 2011; 66: 2092-2098
14. Royce RA, Winkelstein W Jr. HIV infection, cigarette smoking and CD4+T-lymphocyte counts: preliminary results from the San Francisco Mens Health Study. AIDS. 1990; 4: 327-333
15. Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet. 2009; 54: 261-265
16. Flicek P, Ahmed I, Amode MR, et al. Ensembl 2013. Nucleic Acids Res. 2013; 41: D48-D55
17. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007; 8: 547-558
18. Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G . T [Q172H], a marker of CYP2B66, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008; 325: 284-292
19. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol. 2001; 41: 123-143
20. Chang TK, Bandiera SM, Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos. 2003; 31: 7-10
21. Miksys S, Lerman C, Shields PG, et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003; 45: 122-132
22. Abuye C, Tsegaye A, West CE, et al. Determinants of CD4 counts among HIV-negative Ethiopians: role of body mass index, gender, cigarette smoking, khat (Catha Edulis) chewing, and possibly altitude? J Clin Immunol. 2005; 25: 127-133
23. Parry H, Cohen S, Schlarb JE, et al. Smoking, alcohol consumption, and leukocyte counts. Am J Clin Pathol. 1997; 107: 64-67
24. Craib KJ, Schechter MT, Montaner JS, et al. The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men. Clin Invest Med. 1992; 15: 301-308
25. Tollerud DJ, Clark JW, Brown LM, et al. The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. Am Rev Respir Dis. 1989; 139: 1446-1451
26. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B66 and 26. Clin Infect Dis. 2007; 45: 1230-1237
27. Sukasem C, Sungkanuparph S. Would a CYP2B6 test help HIV patients being treated with efavirenz? Pharmacogenomics. 2013; 14: 999-1001
28. Lam YW. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol. 2013; 2013: 641089
29. Lam YWF. Translating pharmacogenomic research to therapeutic potentials. In: Lam YWF, Cavallari LH, eds. Pharmacogenomics-Challenges and Opportunities in Therapeutic Implementation. Oxford: Elsevier; 2013: 45-61